Search Result

Isoforms Recommended:	c-Raf

Results for "

C-Raf

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Raf (41) Apoptosis (7) Atg8/LC3 (1) Aurora Kinase (1) Autophagy (5) Bcr-Abl (2) c-Fms (1) c-Kit (2) Discoidin Domain Receptor (1) Ephrin Receptor (1) FLT3 (1) Isotope-Labeled Compounds (3) JNK (1) MDM-2/p53 (1) MEK (3) Molecular Glues (1) p38 MAPK (1) PDGFR (1) Ras (5) RET (1) ROS Kinase (1) Src (1) VEGFR (2)
By Research Areas:	Cancer (46) Inflammation/Immunology (1) Neurological Disease (2)

Inhibitors & Agonists

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Raf

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15198

KG5	Raf PDGFR FLT3 c-Kit	Cancer
KG5 is an orally active dual PDGFRβ and B-Raf allosteric inhibitor. KG5 also inhibits Flt3, KIT and *c-Raf*. KG5 has anticancer, antiangiogenic activities .

HY-146303

C-RAF kinase-IN-1	Others	Cancer
C-RAF kinase-IN-1 (compound 1l) is a potent inhibitor of *C-RAF* kinase with an IC₅₀ of 0.193 μM. C-RAF kinase-IN-1 is a quinoline derivative. C-RAF kinase-IN-1 has the potential for the research of cancer diseases .

HY-157750

MEK1/C-Raf-IN-1

MEK Raf Cancer

MEK1/C-Raf-IN-1 (Compound 14d) is a MEK1/C-Raf inhibitor with IC₅₀ values of 97 and 23 nM, respectively. MEK1/C-Raf-IN-1 has antitumor activity .

*MEK1/C-Raf-IN-1*	MEK Raf	Cancer
MEK1/C-Raf-IN-1 (Compound 14d) is a *MEK1/C-Raf* inhibitor with IC₅₀ values of 97 and 23 nM, respectively. MEK1/C-Raf-IN-1 has antitumor activity .

HY-156554

Raf inhibitor 3	Raf	Cancer
Raf inhibitor 3 (Example 30) is a Raf inhibitor. Raf inhibitor 3 inhibits B-Raf and C-Raf with IC₅₀ values less than 15 nM. Raf inhibitor 3 can be used for research of cancers .

HY-146442

*BRAF V600E/CRAF-IN-1*	Raf	Cancer
BRAF V600E/CRAF-IN-1 (Compound 8b) is a potent inhibitor of BRAF ^V600E/CRAF. BRAF V600E/CRAF-IN-1 triggers apoptosis and cell cycle arrest at G0/G1 phase in HCT-116 colon cancer cell. BRAF V600E/CRAF-IN-1 has the potential for the research of cancer diseases .

HY-153490

ISIS 5132

CGP 69846A; ISIS 9271
Raf Cancer

ISIS 5132 is a 20-base phosphorothioate oligonucleotide that specifically down-regulates c-raf expression.
HY-153490A

ISIS 5132 sodium

CGP 69846A sodium; ISIS 9271 sodium
Raf Cancer

ISIS 5132 sodium is a 20-base phosphorothioate oligonucleotide that specifically down-regulates c-raf expression.

ISIS 5132 CGP 69846A; ISIS 9271	Raf	Cancer
ISIS 5132 is a 20-base phosphorothioate oligonucleotide that specifically down-regulates c-raf expression.

ISIS 5132 sodium CGP 69846A sodium; ISIS 9271 sodium	Raf	Cancer
ISIS 5132 sodium is a 20-base phosphorothioate oligonucleotide that specifically down-regulates *c-raf* expression.

HY-146443

*BRAF V600E/CRAF-IN-2*	Raf	Cancer
BRAF V600E/CRAF-IN-2 (Compound 9c) is a potent inhibitor of BRAF ^V600E/CRAF with IC₅₀s of 0.888 and 0.229 μM, respectively. BRAF V600E/CRAF-IN-2 triggers apoptosis and cell cycle arrest at G0/G1 phase in HCT-116 colon cancer cell. BRAF V600E/CRAF-IN-2 has the potential for the research of cancer diseases .

HY-14979A

ML786 dihydrochloride	Raf Bcr-Abl Discoidin Domain Receptor VEGFR RET Ephrin Receptor	Cancer
ML786 dihydrochloride is a potent and orally bioavailable Raf inhibitor, with IC₅₀s of 2.1, 4.2, and 2.5 nM for ^V600EΔB-Raf, wt B-Raf, and *C-Raf, respectively. ML786 dihydrochloride also inhibits Abl-1, DDR2, EPHA2, KDR, and RET* (IC₅₀=<0.5, 7.0, 11, 6.2, 0.8 nM). ML786 dihydrochloride can be used for the research of cancers .

HY-13343

ZM 336372 1 Publications Verification	Raf Apoptosis	Cancer
ZM 336372 is a potent inhibitor of the protein kinase *c-Raf. The IC₅₀* value is 0.07 μM in the standard assay, which contains 0.1 mM ATP.

HY-14660A

Dabrafenib Mesylate 40+ Cited Publications GSK2118436 Mesylate; GSK 2118436B	Raf	Cancer
Dabrafenib Mesylate is a potent and selective Raf kinase inhibitor with IC₅₀s of 0.6 and 5.0 nM for Raf ^V600E and c-Raf, respectively.

HY-14660

Dabrafenib 40+ Cited Publications GSK2118436A; GSK2118436	Raf	Cancer
Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC₅₀s of 5 nM and 0.6 nM for *C-Raf* and B-Raf ^V600E, respectively .

HY-14177

Raf inhibitor 1 3 Publications Verification	Raf	Cancer
Raf inhibitor 1 is a potent Raf kinase inhibitor with K_is of 1 nM, 1 nM, and 0.3 nM for B-Raf ^WT, B-Raf ^V600E, and C-Raf, respectively.

HY-15716

Kobe0065 3 Publications Verification	Ras Apoptosis	Cancer
Kobe0065 is a novel and effective inhibitor of Ras-Raf interaction, competitively inhibiting the binding of H-Ras·GTP to c-Raf-1 RBD with a K_i value of 46±13 μM.

HY-14177A

Raf inhibitor 1 dihydrochloride	Raf	Cancer
B-Raf inhibitor 1 dihydrochloride is a potent Raf kinase inhibitor with K_is of 1 nM, 1 nM, and 0.3 nM for B-Raf ^WT, B-Raf ^V600E, and C-Raf, respectively.

HY-11004

AZ 628

5+ Cited Publications

Raf Apoptosis Cancer

AZ 628 is a pan-Raf kinase inhibitor with IC₅₀s of 105, 34 and 29 nM for B-Raf, B-RafV600E, and c-Raf-1, respectively.

AZ 628 5+ Cited Publications	Raf Apoptosis	Cancer
AZ 628 is a pan-Raf kinase inhibitor with IC₅₀s of 105, 34 and 29 nM for B-Raf, B-RafV600E, and *c-Raf-1*, respectively.

HY-10966

SB-590885 4 Publications Verification	Raf	Cancer
SB-590885 is a potent B-Raf inhibitor with K_i of 0.16 nM, and has 11-fold greater selectivity for B-Raf over c-Raf, without inhibition to other human kinases.

HY-15717

Kobe2602

Ras Cancer

Kobe2602 is a Ras-Raf interaction inhibitor. Kobe2602 inhibits the binding of H-Ras·GTP to c-Raf-1 RBD with a K_i of 149 μM. Kobe2602 has antitumor activity .

Kobe2602	Ras	Cancer
Kobe2602 is a Ras-Raf interaction inhibitor. Kobe2602 inhibits the binding of H-Ras·GTP to c-Raf-1 RBD with a K_i of 149 μM. Kobe2602 has antitumor activity .

HY-109080

Belvarafenib 1 Publications Verification HM95573; GDC-5573; RG6185	Raf	Cancer
Belvarafenib (HM95573) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC₅₀s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAF ^v600E and C-RAF respectively .

HY-109080A

Belvarafenib TFA HM95573 TFA; GDC-5573 TFA; RG6185 TFA	Raf	Cancer
Belvarafenib TFA (HM95573 TFA) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC₅₀s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv ^600E and C-RAF respectively .

HY-10542A

(Z)-GW 5074	Atg8/LC3 Raf	Neurological Disease
(Z)-GW 5074 is a compound which interacts with both mHTT (mutant huntingtin protein) and LC3, but not but not with the wild-type HTT protein. (Z)-GW 5074 inhibits *c-Raf*, shows no effect on autophagy, and is effective for neurodegenerative disorder .

HY-14660S

Dabrafenib-d9 GSK2118436A-d₉; GSK2118436-d₉	Isotope-Labeled Compounds Raf	Cancer
Dabrafenib-d₉ is the deuterium labeled Dabrafenib. Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC50s of 5 nM and 0.6 nM for C-Raf and B-RafV600E, respectively[4].

HY-12057

Vemurafenib Maximum Cited Publications 65 Publications Verification PLX4032; RG7204; RO5185426	Raf Autophagy	Cancer
Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC₅₀s of 31 and 48 nM for RAF ^V600E and c-RAF-1, respectively . Vemurafenib induces cell autophagy .

HY-10542

GW 5074 5+ Cited Publications	Raf Apoptosis	Cancer
GW 5074 is a potent and selective *c-Raf* inhibitor with IC₅₀ of 9 nM, and has no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms .

HY-126298

RAF mutant-IN-1	Raf	Cancer
RAF mutant-IN-1 is a RAF kinase inhibitor, extracted from patent WO2019107987A1, with IC₅₀ values of 21 nM, 30 nM and 392 nM for C-RAF ^340D/Y341D, B-RAF ^V600E and B-RAF ^WT, respectively .

HY-12057S

Vemurafenib-d5	Isotope-Labeled Compounds Raf Autophagy	Cancer
Vemurafenib-d₅ is the deuterium labeled Vemurafenib. Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively[1][4]. Vemurafenib induces cell autophagy[5].

HY-12057S1

Vemurafenib-d7 PLX4032-d₇; RG7204-d₇; RO5185426-d₇	Isotope-Labeled Compounds Raf Autophagy	Cancer
Vemurafenib-d₇ is deuterium labeled Vemurafenib. Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively[1][4]. Vemurafenib induces cell autophagy[5].

HY-51424

PLX-4720 5+ Cited Publications	Raf	Cancer
PLX-4720 is a potent and selective inhibitor of B-Raf ^V600E with IC₅₀ of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-Raf ^V600E than wild-type B-Raf.

HY-10204

OSI-930 4 Publications Verification	c-Kit VEGFR c-Fms Apoptosis	Cancer
OSI-930 is an orally selective inhibitor of Kit, KDR and CSF-1R (c-Fms) with IC₅₀s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits Flt-1, *c-Raf, Lck* and low activity against PDGFRα/β, Flt-3 and Abl. OSI-930 has antitumor activity .

HY-51424S

PLX-4720-d7	Raf	Cancer
PLX-4720-d₇ is the deuterium labeled PLX-4720. PLX-4720 is a potent and selective inhibitor of B-RafV600E with an IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf[1][2].

HY-11010

AS601245 5 Publications Verification	JNK	Neurological Disease Inflammation/Immunology Cancer
AS601245 is an orally active, selective, ATP competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC₅₀s of 150, 220, and 70 nM for three JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively. AS601245 exhibits 10- to 20-fold selectivity over c-src, CDK2, and c-Raf and more than 50- to 100-fold selectivity over a range of Ser/Thr- and Tyr-protein kinases. Neuroprotective properties .

HY-112089

Naporafenib 2 Publications Verification LXH254	Raf p38 MAPK Bcr-Abl	Cancer
Naporafenib (LXH254) is a potent, selective, orally active, type II BRAF and *CRAF* inhibitor, with IC₅₀ values of 0.072 and 0.21 nM against CRAF and BRAF, respectively .

HY-144271

RAF-IN-1	Raf	Cancer
RAF-IN-1 is a potent *b/cRAF* inhibitor with an IC₅₀s of 3.8 nM, 36 nM, 29.4 nM for cRAF, bRAF ^wt, and bRAF ^V600E. RAF-IN-1 shows cell growth inhibition with GI₅₀s of 3.4 and 2.9 nM for H358 and A375 cell line bearing bRAF ^V600E mutation, respectively .

HY-100510

RAF709 5+ Cited Publications	Raf	Cancer
RAF709 is a potent, selective, and efficacious RAF inhibitor with IC₅₀s of 0.4 nM and 0.5 nM for BRAF and *CRAF*, respectively . Antitumor efficacy .

HY-15767

TAK-632

3 Publications Verification

Raf Aurora Kinase Cancer

TAK-632 is a potent pan-RAF inhibitor with IC₅₀ of 1.4, 2.4 and 8.3 nM for CRAF, BRAF ^V600E, BRAF ^WT, respectively.
HY-13810

PF-04880594

Raf Cancer

PF-04880594 is a potent and selective RAF inhibitor. PF-04880594 inhibits both wild-type and mutant BRAF and CRAF. PF-04880594 shows antitumor activity .

TAK-632 3 Publications Verification	Raf Aurora Kinase	Cancer
TAK-632 is a potent pan-RAF inhibitor with IC₅₀ of 1.4, 2.4 and 8.3 nM for *CRAF, BRAF ^V600E, BRAF ^WT*, respectively.

PF-04880594	Raf	Cancer
PF-04880594 is a potent and selective RAF inhibitor. PF-04880594 inhibits both wild-type and mutant BRAF and CRAF. PF-04880594 shows antitumor activity .

HY-18652

Avutometinib 1 Publications Verification Ro 5126766; CH5126766	MEK Raf	Cancer
Avutometinib (Ro 5126766) is a first-in-class dual MEK/RAF inhibitor that allosterically inhibits BRAF ^V600E, *CRAF, MEK, and BRAF* (IC₅₀: 8.2, 56, 160 nM, and 190 nM, respectively).

HY-12846

CCT196969

Raf Cancer

CCT196969 is a pan-Raf inhibitor, which inhibits B-Raf, BRaf ^V600E and CRAF with IC₅₀s of 0.1, 0.04, and 0.01 μM, respectively.

CCT196969	Raf	Cancer
CCT196969 is a pan-Raf inhibitor, which inhibits B-Raf, BRaf ^V600E and *CRAF* with IC₅₀s of 0.1, 0.04, and 0.01 μM, respectively.

HY-12558

LY3009120 10+ Cited Publications DP-4978	Raf Autophagy	Cancer
LY3009120 (DP-4978) is a pan RAF inhibitor which inhibits BRAF ^V600E, BRAF ^WT and CRAF ^WT with IC₅₀s of 5.8, 9.1 and 15 nM, respectively.

HY-12847

CCT241161	Raf Src Apoptosis	Cancer
CCT241161 is an orally active pan-RAF inhibitor with IC₅₀s of 3, 6, 10, 15 and 30 nM for LCK, *CRAF, SRC, V600E-BRAF* and BRAF, respectively. CCT241161 shows good activity to in BRAF and NRAS mutant melanomas. CCT241161 also exhibits anticancer cell proliferative activity .

HY-117273

AZ304	Raf Autophagy	Cancer
AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits wild type BRAF, V600E mutant BRAF and wild type CRAF, with IC₅₀s of 79 nM, 38 nM and 68 nM, respectively. AZ304 also has significant effect on other kinases, such as p38 (IC₅₀, 6 nM), CSF1R (IC₅₀, 35 nM). Anti-tumor activity .

HY-153663

TH-Z827	Ras	Cancer
TH-Z827 is a mutant selective KRAS(G12D) inhibitor with an IC₅₀ of 2.4 μM. TH-Z827 does not bind KRAS(WT) or KRAS(G12C). TH-Z827 blocked the KRAS(G12D)-CRAF interaction with an IC₅₀ value of 42 μM .

HY-142160

GNE-9815	Raf	Cancer
GNE-9815 (compound 7) is a highly selective, pan-RAF inhibitor with good oral bioavailability. GNE-9815 exhibits K_i values of 0.062 and 0.19 nM for *CRAF* and BRAF, respectively. GNE-9815 combines with MEK inhibitor Cobimetinib (HY-13064) shows synergistic modulation of MAPK pathway. GNE-9815 can be used in studies of KRAS mutant cancers .

HY-107779

BI-882370	Raf	Cancer
BI-882370 is a potent and selective RAF kinase inhibitor that binds to the ATP binding site of the kinase positioned in the DFG-out (inactive) conformation of the BRAF kinase. BI-882370 (BI 882370) inhibits the oncogenic BRAF ^V600E-mutant, the WT BRAF and CRAF kinases with IC₅₀s of 0.4, 0.8, and 0.6 nM, respectively. BI-882370 also inhibits SRC family kinases .

HY-158115

NST-628	Molecular Glues Raf MEK	Cancer
NST-628 is a brain-permeable MAPK pathway molecule glue that inhibits RAF phosphorylation and MEK activation. NST-628 also binds RAF and prevents the formation of BRAF-CRAF and BRAF-ARAF heterodimers, effectively inhibiting the RAS-MAPK pathway. NST-628 inhibits RAS- and RAF-driven cancers and demonstrated potent inhibition in mutant KRAS, NRAS, BRAF class II/III, and NF1-mutant tumors .

HY-144269

SHR902275	Raf	Cancer
SHR902275 is a potent, selective, and orally active RAF inhibitor targeting RAS mutant cancers. SHR902275 has IC₅₀s of 1.6 nM, 10 nM, and 5.7 nM for cRAF, bRAF ^wt, and bRAF ^V600E, respectively. SHR902275 shows cell growth inhibition with GI₅₀s of 1.5 and 0.17 nM, 0.4 nM and 0.32 nM for H358, A375, Calu6, and SK-MEL2 cells respectively .

HY-122862

RAS inhibitor Abd-7 1 Publications Verification	Ras	Cancer
RAS inhibitor Abd-7, a potent RAS-binding compound (K_d=51 nM), is a RAS-effector protein-protein interaction (PPI) inhibitor. RAS inhibitor Abd-7 interacts with RAS inside the cells, prevents RAS-effector interactions and inhibits endogenous RAS-dependent signaling. RAS inhibitor Abd-7 impairs the PPI of various mutant KRAS proteins with PI3K, CRAF and RALGDS as well as NRAS Q61H and HRAS G12V .

HY-146432

Antitumor agent-60	Apoptosis Raf Ras ROS Kinase MDM-2/p53
Antitumor agent-60 (compound 20) is a potent antitumor agent, targeting RAS-RAF signaling pathway and binding to *CRAF* with a K_d value of 3.93 μM. Antitumor agent-60 induces apoptosis by blocking cell cycle at G2/M phase. Antitumor agent-60 enhances the level of p53 and ROS. Antitumor agent-60 causes oval and irregular nucleus in cancer cells. Antitumor agent-60 can suppress the growth of tumor to some extent in A549 xenograft model .

Cat. No.	Compare	Product Name	Species	Source

HY-P702733

	RAF1 Protein, Human (Y340D,Y341D, sf9, His, GST) Raf1; Raf-1 proto-oncogene, serine/threonine kinase; NS5; CRaf; Raf-1; c-Raf; CMD1NN; Raf proto-oncogene serine/threonine-protein kinase; C-Raf proto-oncogene, serine/threonine kinase; Oncogene Raf1; proto-oncogene c-Raf; Raf proto-oncogene serine/threonine protein kinase; v-Raf-1 murine leukemia viral oncogene homolog 1; v-Raf-1 murine leukemia viral oncogene-like protein 1; EC 2.7.11.1	Human	Sf9 insect cells

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote